SECTION 1: (a) As used in this section, the following words shall have the following meanings, unless the context clearly requires otherwise:-

“HIV”, human immunodeficiency virus.

“HIV prevention drug”, any preexposure prophylaxis drug approved for the prevention of HIV by the federal Food and Drug Administration, including any ancillary or support health service determined by the secretary of health and human services that is necessary to: (1) ensure that such a drug is prescribed or administered to a person who is not infected with HIV and has no medical contraindications to the use of such a drug; and (2) monitor such a person to ensure the safe and effective ongoing use of such a drug through: (A) an office visit; (B) laboratory testing; (C) testing for a sexually transmitted infection; (D) medication self-management and adherence counseling; (E) or any other health service specified as part of comprehensive HIV prevention drug services by the United States Department of Health and Human Services, the United States Centers for Disease Control and Prevention or the United States Preventive Services Task Force.

(b)(1) Notwithstanding any general or special law to the contrary, any policy, contract or certificate of health insurance subject to chapters 32A, 118E, 175, 176A, 176B, 176G, 176I, 176J or 176Q of the General Laws that provides coverage for any HIV prevention drug shall not require:

(A) any cost-sharing, including co-payments or co-insurance, or any deductible; and

(B) prior authorization, step therapy or any other protocol that could restrict or delay the dispensing or provision of any HIV prevention drug. 

(2) The commissioner of the division of insurance, in consultation with the secretary of health and human services, shall adopt any written policies, procedures or regulations necessary to implement this subsection.